. "Hyperaktivn\u00ED m\u011Bch\u00FD\u0159 u \u017Een"@cs . . "RIV/00064203:_____/12:8656" . "Hyperaktivn\u00ED m\u011Bch\u00FD\u0159 u \u017Een" . . . "Hoftov\u00E1, Kate\u0159ina" . "1212-4184" . "3" . "[C090ABB671FA]" . . . "14" . "Hyperactive bladder in women"@en . . "RIV/00064203:_____/12:8656!RIV13-MZ0-00064203" . "CZ - \u010Cesk\u00E1 republika" . . . . "Brtnick\u00FD, Tom\u00E1\u0161" . . "http://zdravi.e15.cz/archiv/postgradualni-medicina/?id=3809" . . "Hyperactive bladder; women"@en . "Postgradu\u00E1ln\u00ED medic\u00EDna" . . "Hyperaktivn\u00ED m\u011Bch\u00FD\u0159 je souhrnem symptom\u016F maj\u00EDc\u00EDch r\u016Fzn\u00E9 p\u0159\u00ED\u010Diny a jeho prevalence stoup\u00E1 v souvislosti s v\u011Bkem \u017Een. Diagnostika je velmi jednoduch\u00E1, zalo\u017Een\u00E1 na anamnestick\u00FDch informac\u00EDch, v nich\u017E dominuje pocit urgence (n\u00E1hl\u00E9 a siln\u00E9 nucen\u00ED na mo\u010Den\u00ED, kter\u00E9 lze t\u011B\u017Eko potla\u010Dit), s projevy inkontinence nebo bez n\u00ED, zpravidla s \u010Dastou mikc\u00ED (v\u00EDce ne\u017E 8kr\u00E1t za 24 hodin) a opakovan\u00FDm no\u010Dn\u00EDm mo\u010Den\u00EDm (nykturie). Terapie je zalo\u017Een\u00E1 na dvou z\u00E1kladn\u00EDch principech: na aktivn\u00EDm p\u0159\u00EDstupu \u017Eeny a na l\u00E9ka\u0159em p\u0159edepsan\u00E9 farmakoterapii. V l\u00E9\u010Db\u011B hyperaktivn\u00EDho m\u011Bch\u00FD\u0159e se pou\u017E\u00EDvaj\u00ED hlavn\u011B l\u00E9ky s anticholinergn\u00EDm p\u016Fsoben\u00EDm. \u00DA\u010Dinnost terapie je vysok\u00E1, p\u0159i\u010Dem\u017E limituj\u00EDc\u00EDm faktorem dlouhodob\u00E9 efektivity jsou ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky (zejm\u00E9na sucho v \u00FAstech a obstipace). Velmi \u010Dast\u00FD dopln\u011Bk l\u00E9\u010Dby anticholinergiky v postmenopauze p\u0159edstavuje lok\u00E1ln\u00ED vagin\u00E1ln\u00ED estrogenn\u00ED terapie. Zlep\u0161en\u00ED urogenit\u00E1ln\u00ED trofiky a senzitivity urogenit\u00E1ln\u00EDho traktu m\u016F\u017Ee v\u00E9st ke sn\u00ED\u017Een\u00ED d\u00E1vek pou\u017Eit\u00FDch anticholinergik p\u0159i zachov\u00E1n\u00ED efektivity a zlep\u0161en\u00ED compliance \u017Een v dlouhodob\u00E9 l\u00E9\u010Db\u011B hyperaktivn\u00EDho m\u011Bch\u00FD\u0159e."@cs . . "Chmel, Roman" . "5"^^ . "Nov\u00E1\u010Dkov\u00E1, Marta" . "140093" . "Hyperaktivn\u00ED m\u011Bch\u00FD\u0159 u \u017Een"@cs . . "Hyperactive bladder is the term for a sum of symptoms with different causes and its prevalence increases with age. The diagnostic process is very simple and it is based on case history with a focus of urgency (sudden and strong urge to urinate that is very difficult to suppress), the presence of incontinence or lack thereof, the frequency of micturition (more than 8 times per 24 hours) and repeated urination during night (nocturia). The therapy is based on two main principles: the patients active approach and prescribed pharmacotherapy. Anticholinergic drugs are main mode of treatment used for hyperactive bladder symptoms. Efficacy is high but the side effects of anticholinergics (mainly dry mouth and constipation) are limiting factors their usage in long-term treatment. Vaginal oestrogen therapy is very often added to anticholinergics in postmenopausal women. Positive effects on urogenital atrophy and urogenital tract sensitivity may lead to reduction of anticholinergic doses with preservation of efficacy and to improved compliance with the longterm treatment."@en . "Hyperaktivn\u00ED m\u011Bch\u00FD\u0159 je souhrnem symptom\u016F maj\u00EDc\u00EDch r\u016Fzn\u00E9 p\u0159\u00ED\u010Diny a jeho prevalence stoup\u00E1 v souvislosti s v\u011Bkem \u017Een. Diagnostika je velmi jednoduch\u00E1, zalo\u017Een\u00E1 na anamnestick\u00FDch informac\u00EDch, v nich\u017E dominuje pocit urgence (n\u00E1hl\u00E9 a siln\u00E9 nucen\u00ED na mo\u010Den\u00ED, kter\u00E9 lze t\u011B\u017Eko potla\u010Dit), s projevy inkontinence nebo bez n\u00ED, zpravidla s \u010Dastou mikc\u00ED (v\u00EDce ne\u017E 8kr\u00E1t za 24 hodin) a opakovan\u00FDm no\u010Dn\u00EDm mo\u010Den\u00EDm (nykturie). Terapie je zalo\u017Een\u00E1 na dvou z\u00E1kladn\u00EDch principech: na aktivn\u00EDm p\u0159\u00EDstupu \u017Eeny a na l\u00E9ka\u0159em p\u0159edepsan\u00E9 farmakoterapii. V l\u00E9\u010Db\u011B hyperaktivn\u00EDho m\u011Bch\u00FD\u0159e se pou\u017E\u00EDvaj\u00ED hlavn\u011B l\u00E9ky s anticholinergn\u00EDm p\u016Fsoben\u00EDm. \u00DA\u010Dinnost terapie je vysok\u00E1, p\u0159i\u010Dem\u017E limituj\u00EDc\u00EDm faktorem dlouhodob\u00E9 efektivity jsou ne\u017E\u00E1douc\u00ED \u00FA\u010Dinky (zejm\u00E9na sucho v \u00FAstech a obstipace). Velmi \u010Dast\u00FD dopln\u011Bk l\u00E9\u010Dby anticholinergiky v postmenopauze p\u0159edstavuje lok\u00E1ln\u00ED vagin\u00E1ln\u00ED estrogenn\u00ED terapie. Zlep\u0161en\u00ED urogenit\u00E1ln\u00ED trofiky a senzitivity urogenit\u00E1ln\u00EDho traktu m\u016F\u017Ee v\u00E9st ke sn\u00ED\u017Een\u00ED d\u00E1vek pou\u017Eit\u00FDch anticholinergik p\u0159i zachov\u00E1n\u00ED efektivity a zlep\u0161en\u00ED compliance \u017Een v dlouhodob\u00E9 l\u00E9\u010Db\u011B hyperaktivn\u00EDho m\u011Bch\u00FD\u0159e." . . "Hyperactive bladder in women"@en . "4"^^ . "I" . "4"^^ . . "Hyperaktivn\u00ED m\u011Bch\u00FD\u0159 u \u017Een" .